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Abstract
The complement system forms the central core of innate immunity but also mediates a variety of
inflammatory responses. Anaphylatoxin C3a, which is generated as a byproduct of complement
activation, has long been known to activate mast cells, basophils and eosinophils and to cause
smooth muscle contraction. However, the role of C3a in the pathogenesis of allergic asthma
remains unclear. In this review, we examine the role of C3a in promoting asthma. Following
allergen challenge, C3a is generated in the lung of subjects with asthma but not healthy subjects.
Furthermore, deficiency in C3a generation or in G protein coupled receptor for C3a abrogates
allergen-induced  responses in murine models of pulmonary inflammation and airway
hyperresponsiveness. In addition, inhibition of complement activation or administration of small
molecule inhibitors of C3a receptor after sensitization but before allergen challenge inhibits airway
responses. At a cellular level, C3a stimulates robust mast cell degranulation that is greatly enhanced
following cell-cell contact with airway smooth muscle (ASM) cells. Therefore, C3a likely plays an
important role in asthma primarily by regulating mast cell-ASM cell interaction.
Role of complement system in the development 
of asthma
Asthma, a complex airway inflammatory disease, is char-
acterized by bronchoconstriction, airway hyperrespon-
siveness (AHR) and remodeling. Current consensus
suggests that TH2 cytokine producing T cells, mast cells
and ASM cells play central roles in the pathogenesis of
asthma [1-7]. The complement system forms an impor-
tant part of innate immunity against bacteria and other
pathogens. As a system of 'pattern recognition molecules',
foreign surface antigens and immune complexes initiate a
proteolytic pathway leading to the formation of a lytic
membrane attack complex. The anaphylatoxins C3a and
C5a are released as byproducts of complement activation
and modulate innate immunity. Accordingly, C5a is
involved in a number of inflammatory diseases such as
immune-complex-mediated lung injury and sepsis [8,9].
A role for C3a in innate or adaptive immunity, however,
has only been recently recognized [10].
C3a levels are elevated in bronchoalveolar lavage (BAL)
fluid after segmental allergen challenge in asthmatic but
not healthy subjects [11-14]. Furthermore, plasma C3a is
also elevated in acute exacerbations of asthma [11]. Addi-
tionally, single nucleotide polymorphisms in C3 and C3a
receptor genes increases susceptibility to asthma [15].
Collectively, these findings suggest that C3a and the cog-
nate G protein coupled receptor (C3aR) may play a role in
the development of airway hyperresponsiveness (AHR)
and inflammation.
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Studies with animal models provided compelling evi-
dence for C3aR activation in the development of AHR and
inflammation. Humbles et al., [12], showed that C3aR (-
/-) mice in BALB/c strain are protected from AHR in
response to aerosolized ovalbumin challenge following
intraperitoneal sensitization with ovalbumin [12]. How-
ever, C3aR (-/-) mice developed normal airway inflamma-
tory response with no difference in TH2 cytokine
production and eosinophil recruitment in BAL when
compared to wild-type mice. Additionally, guinea pigs
with a natural defect in C3aR expression were also pro-
tected from AHR in response ovalbumin to challenge with
no effect on airway inflammation [16]. These initial find-
ings suggested that C3a modulates AHR, perhaps, via a
direct action on airway smooth muscle cells [12,17,18].
Recent studies using C3aR (-/-) mice provided new
insights on the role of C3a on both AHR and airway
inflammation [19]. When sensitized intraperitoneally
with extracts of Aspergillus fumigatous and challenged
intranasally with allergen, these mice experienced sub-
stantial decreases in both AHR and airway eosinophilia
relative to wild-type mice. Furthermore, BAL levels of TH2
cytokines (IL-4, IL-5, IL-13), IgE titres and mucous pro-
duction were all significantly reduced in C3aR (-/-) mice.
Allergen-challenged C3 (-/-) mice also display diminished
AHR, lung eosinophilia and TH2 cytokine production
when compared to wild-type mice [20]. These findings
support a role of C3a receptors in the development of
AHR and inflammation. However, the effect of C3aR on
different phases of AHR models may depend on the
nature of the allergen, method of sensitization and the
strain of mice used.
C3a generation in asthma
Increased level of C3a in BAL of subjects with asthma
implies a potential role for this apaphylatoxin in promot-
ing airway inflammation. However, the cells responsible
for C3a generation and the airway effector cells stimulated
by C3a remain unknown. Plausibly, antibody generated
during antigen sensitization may interact with allergen to
activate the classical complement pathway. Additionally,
airway epithelial cells and pulmonary macrophages
secrete both C3 and several components of the alternate
pathway of complement (factors B, H, and I and proper-
din) [21-23]. Thus, activation of alternative or the lectin
pathway on the allergen may also lead to the generation
of C3a. It is noteworthy that house dust mite protease,
allergenic extracts of Aspergillus fumigatous and mast cell
tryptase also activate the complement pathway directly
[13,24-26]. Thus, combination of different pathways
likely generates C3a in the airway of individuals with
asthma (Figure 1).
C3a has little effect on allergen sensitization in 
models of AHR
Both antigen-presenting cells (APCs) and activated T cells
express C3aR [27-30], raising the possibility C3a may reg-
ulate sensitization phase of allergic asthma. Kawamoto et
al [31], recently used wild-type and C3aR-/- mice to char-
acterize the immune response to C3a. Convincingly, C3aR
deficiency had little effect on TH2 cytokine response to
intraperitoneal ovalbumin sensitization. Furthermore,
C3a had no effect on TH2 cytokine production in response
to T cell receptor ligation. Further, Taube et al., [32]
showed that administration of complement inhibitor in
mice after sensitization but before allergen challenge pre-
vented the development of AHR and blocked TH2
cytokine production and lung inflammation. Addition-
ally, a small molecule antagonist of C3a receptor, when
administered after sensitization but before challenge also
caused significant inhibition of airway inflammation
[33]. These findings suggest that the effect of C3a on the
development of allergic AHR may not involve modulation
of the sensitization phase of the disease.
Model for C3a generation in individuals with asthmaFigure 1
Model for C3a generation in individuals with asthma. 
C3 may be secreted from pulmonary resident cells (e.g. epi-
thelial cells and macrophages) or derived from plasma leak-
age. Antibody (IgG) present in the serum of sensitized 
individual can form a complex with allergen to activate com-
plement via the classical pathway. Proteases derived from 
allergen or released from activated mast cells are able to 
cleave C3 to generate C3a. Activation of alternative or the 
lectin pathway on the allergen together with factors B, H, 
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Mast cells appear to play a pivotal role in the development
of AHR and inflammation [34]. The ability of allergen to
cross-link high affinity IgE receptors (FcεRI) on mast cells
to induce degranulation and leukotriene generation is
well documented [35,36]. Surprisingly, the role of C3a in
mast cell activation remains controversial and appears to
depend on the mast cells subtype. For example, murine
bone marrow-derived mast cells and a rat basophilic
leukemia, RBL-2H3 cells, which have been used exten-
sively as mast cell models, do not express C3a receptors
[37]. In contrast, C3a receptors are expressed in human
CD34+-derived primary mast cell cultures [38,39], human
mast cell lines HMC-1 [40,41] and LAD 2 [39] as well as
murine pulmonary mast cells (Thangam, B and Ali, H,
unpublished data). Interestingly, C3a is one of the most
potent mast cell chemoattractants known [42,43]. C3a
also induces robust mast cell degranulation [38,39] and
leukotriene C4 generation (Thangam, B and Ali, H,
unpublished data). These findings suggest that allergen
induces mast cell degranulation by at least two mecha-
nisms: cross-linking of FcεRI and via C3a generation fol-
lowing complement activation by allergen protease
(Figure 2). Mast cell proteases also activate the comple-
ment pathway to generate C3a [26]. Therefore, C3a gener-
ation following FcεRI aggregation may amplify mast cell
mediator release (Figure 2).
Mast cell-ASM interaction in asthma
Recent studies with immunohistological analysis of bron-
chial biopsy specimens from subjects with asthma and
those from patients with eosinophilic bronchitis provided
important insight on the role of mast cell-ASM cell inter-
action in the development of AHR in asthma [4,44,45].
Asthma and eosinophilic bronchitis are characterized by
similar inflammatory infiltrates in the submucosa of the
lower airway. However, ASM infiltration by mast cells is a
feature of asthma and not eosinophilic bronchitis. This
difference in mast cell recruitment in asthma is associated
with AHR, which is absent in in eosiniphilic bronchitis
[6]. Furthermore, degranulated mast cells are detected in
greater number in ASM bundles of patients who died from
asthma when compared to non-asthmatic control [46].
Based on these findings, new hypothesis suggests that
increased mast cell recruitment and interaction with ASM
may promote release of mast cell-derived mediators that
modulate resident airway cell function is asthma [4,5,44].
ASM is not only a contractile tissue that responds to mast
cell-derived mediators in asthma, but also modulates
mast cell function and airway inflammation. ASM cells
express stem cell factor (SCF), which induce mast cell
chemotaxis, survival and differentiation [47,48]. Inter-
leukin-1β, tumor necrosis factor (TNF) and TH2 cytokines
IL-4 and IL-13 derived cytokines also stimulate ASM to
express a large number of chemokines and cytokines [49-
52]. Thus, activated ASM cells secrete chemokines and
cytokines that may recruit and retain mast cells into the
ASM.
C3a receptors and mast cell-ASM cell 
interaction
C3a has long been recognized as an agent that evokes
force generation in smooth muscle. In guinea pigs, C3a-
induced contraction of lung parenchyma may involve
indirect effects of histamine and arachidonic acid metab-
olites [53]. In mice, C3a does not cause shortening of iso-
lated tracheal strips [10]. Furthermore, C3a fails to induce
AHR after intratracheal instillation in naïve mice [10]. In
contrast, in mice immunized with house dust mite, subse-
quent intratracheal administration of C3a stimulates both
AHR and airway inflammation [10]. These findings sug-
gest that C3a-induced AHR and bronchoconstriction
requires enhanced infiltration and activation of inflam-
matory cells, likely mast cells.
Recently, investigations showed that human mast cells
but not human or murine ASM express C3aR [54]. Inter-
estingly, incubation of mast cells with human ASM cells,
but not its culture supernatant, significantly enhanced
Proposed interaction between FεRI and C3aR leading to mast cell activationFigur  2
Proposed interaction between FcεRI and C3aR lead-
ing to mast cell activation. Allergen cross-links FcεRI on 
mast cells to induce degranulation. Allergen can also activate 
complement pathway (see Fig. 1) to generate C3a, which in 
turn activates its cognate G protein coupled receptors on 
mast cells to induce degranulation. Mast cell proteases also 
activates complement cascade to generate C3a. This C3a 
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factor (SCF) and its receptor c-kit are constitutively
expressed on ASM cells and mast cells respectively, neu-
tralizing antibodies to SCF and c-kit failed to inhibit ASM
cell-mediated enhancement of mast cell degranulation.
Dexamethasone-treated ASM cells however normally
express cell surface SCF but were significantly less effective
in enhancing C3a-induced mast cell degranulation when
compared to untreated cells. Collectively, these findings
suggest that cell-cell interaction between ASM cells and
mast cells, via a SCF-c-kit independent but dexametha-
sone-sensitive mechanism, enhances C3a-induced mast
cell degranulation, which likely regulates ASM function
and may contribute to the pathogenesis of asthma.
While mast cells and ASM cell interaction plays a role in
AHR, airway inflammation in asthma is strongly linked to
TH2 lymphocyte and their cytokines IL-4, IL-5 and IL-13.
These cytokines play key roles in the recruitment and acti-
vation of eosinophil, mucous production and IgE synthe-
sis. Allergen challenge of sensitized C3 (-/-) and C3aR (-/-
) mice decreased production of TH2 cytokines in BAL and
substantially reduced recruitment of T cells, eosinophils
and neutrophils in lung tissue [19,20]. Furthermore, inhi-
bition of complement activation or administration of
C3aR antagonist during the effector phase of asthma sub-
stantially inhibited airway inflammation [32,33]. These
findings suggest activation of C3aR is required for TH2
effector function in murine model of allergen-induced
inflammation. Accordingly, in human mast cells, C3a
stimulates the production of MCP-1, RANTES [39], IL-8
and IL-13 (Thangam, B and Ali, H, unpublished data)-
cytokines and chemokines are responsible for the recruit-
ment of T lymphocytes, eosinophils and neutrophils into
the airway. Further, C3aR are expressed on basophils,
eosinophils and bronchial epithelial cells [18,54-57].
Thus, interaction of a number of inflammatory and resi-
dent cells likely regulate C3a-dependent TH2 cytokine and
chemokine production in asthma (Figure 3).
Conclusion
Accumulating evidence suggests that C3a may play an
important role in the pathogenesis of asthma. In murine
models of allergic AHR and inflammation, inhibition of
complement activation or small molecule antagonists of
C3a receptor after sensitization but before allergen chal-
lenge inhibits airway responses. Furthermore, cell-cell
interaction between ASM cells and mast cells enhances
C3a-induced mast cell degranulation, which likely regu-
lates ASM function, thus contributing to the pathogenesis
of asthma. Further investigations on cellular and molecu-
lar mechanisms by which C3a modules mast cell-ASM
interactions may offer novel therapeutic approaches to the
treatment of asthma and airway inflammation.
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